# Birchtech Corp.: financial statements, quarterly

BCHT · NYSE · CIK 728385 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcht.md) · [Financials](/companies/bcht/financials.md) · [Filings](/companies/bcht/filings.md) · [Insiders](/companies/bcht/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcht/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6,747](/filings/0001477932-24-007130.md) | [3,754 d](/filings/0001477932-25-002237.md) | [3,242](/filings/0001477932-25-003808.md) | [3,361](/filings/0001477932-25-005905.md) | [5,237](/filings/0001477932-25-008185.md) | [5,566 d](/filings/0001477932-26-001835.md) | [3,221](/filings/0001477932-26-003054.md) | [3,254](/filings/0001477932-26-004988.md) | [7,362](/filings/0001477932-25-008185.md) | [3,790 d](/filings/0001477932-26-001835.md) | [4,240](/filings/0001477932-26-003054.md) | [3,791](/filings/0001477932-26-004988.md) |
| Cost of revenue | $k | [4,472](/filings/0001477932-24-007130.md) | [3,054 d](/filings/0001477932-25-002237.md) | [2,113](/filings/0001477932-25-003808.md) | [2,301](/filings/0001477932-25-005905.md) | [3,642](/filings/0001477932-25-008185.md) | [2,249 d](/filings/0001477932-26-001835.md) | [1,987](/filings/0001477932-26-003054.md) | [2,286](/filings/0001477932-26-004988.md) | [3,330](/filings/0001477932-25-008185.md) | [2,623 d](/filings/0001477932-26-001835.md) | [2,857](/filings/0001477932-26-003054.md) | [2,758](/filings/0001477932-26-004988.md) |
| Gross profit | $k | [2,275](/filings/0001477932-24-007130.md) | [700 d](/filings/0001477932-25-002237.md) | [1,128](/filings/0001477932-25-003808.md) | [1,061](/filings/0001477932-25-005905.md) | [1,595](/filings/0001477932-25-008185.md) | [3,317 d](/filings/0001477932-26-001835.md) | [1,234](/filings/0001477932-26-003054.md) | [968](/filings/0001477932-26-004988.md) | [4,032](/filings/0001477932-25-008185.md) | [1,167 d](/filings/0001477932-26-001835.md) | [1,383](/filings/0001477932-26-003054.md) | [1,033](/filings/0001477932-26-004988.md) |
| Research and development | $k | not reported | not reported | [0.0](/filings/0001477932-25-003808.md) | [0.0](/filings/0001477932-25-005905.md) | [0.0](/filings/0001477932-25-008185.md) | [0.0 d](/filings/0001477932-26-001835.md) | [407](/filings/0001477932-26-003054.md) | [455](/filings/0001477932-26-004988.md) | [473](/filings/0001477932-25-008185.md) | [470 d](/filings/0001477932-26-001835.md) | [551](/filings/0001477932-26-003054.md) | [587](/filings/0001477932-26-004988.md) |
| Selling, general and administrative | $k | [2,459](/filings/0001477932-24-007130.md) | [8,047 d](/filings/0001477932-25-002237.md) | [3,527](/filings/0001477932-25-003808.md) | [4,634](/filings/0001477932-25-005905.md) | [2,702](/filings/0001477932-25-008185.md) | [3,353 d](/filings/0001477932-26-001835.md) | [2,171](/filings/0001477932-26-003054.md) | [1,698](/filings/0001477932-26-004988.md) | [2,748](/filings/0001477932-25-008185.md) | [1,960 d](/filings/0001477932-26-001835.md) | [1,981](/filings/0001477932-26-003054.md) | [2,068](/filings/0001477932-26-004988.md) |
| Operating income | $k | [(184)](/filings/0001477932-24-007130.md) | [(7,567) d](/filings/0001477932-25-002237.md) | [(2,398)](/filings/0001477932-25-003808.md) | [(3,574)](/filings/0001477932-25-005905.md) | [(1,107)](/filings/0001477932-25-008185.md) | [(78.8) d](/filings/0001477932-26-001835.md) | [(1,343)](/filings/0001477932-26-003054.md) | [(1,185)](/filings/0001477932-26-004988.md) | [811](/filings/0001477932-25-008185.md) | [(1,313) d](/filings/0001477932-26-001835.md) | [(1,149)](/filings/0001477932-26-003054.md) | [(1,623)](/filings/0001477932-26-004988.md) |
| Interest expense | $k | [344](/filings/0001477932-24-007130.md) | [343 d](/filings/0001477932-25-002237.md) | [246](/filings/0001477932-25-003808.md) | [5.8](/filings/0001477932-25-005905.md) | [7.4](/filings/0001477932-25-008185.md) | [8.5 d](/filings/0001477932-26-001835.md) | [0.1](/filings/0001477932-26-003054.md) | [0.0](/filings/0001477932-25-005905.md) | [0.0](/filings/0001477932-25-008185.md) | [13.6 d](/filings/0001477932-26-001835.md) | [0.0](/filings/0001477932-26-003054.md) | [0.0](/filings/0001477932-26-004988.md) |
| Income tax | $k | [0.0](/filings/0001477932-24-007130.md) | [473 d](/filings/0001477932-25-002237.md) | [0.0](/filings/0001477932-25-003808.md) | [0.3](/filings/0001477932-25-005905.md) | [(294)](/filings/0001477932-25-008185.md) | [4.7 d](/filings/0001477932-26-001835.md) | [14.1](/filings/0001477932-26-003054.md) | [0.4](/filings/0001477932-26-004988.md) | [0.6](/filings/0001477932-25-008185.md) | [54.9 d](/filings/0001477932-26-001835.md) | [0.4](/filings/0001477932-26-003054.md) | [3.4](/filings/0001477932-26-004988.md) |
| Net income | $k | [(828)](/filings/0001477932-24-007130.md) | [8,707 d](/filings/0001477932-25-002237.md) | [(2,855)](/filings/0001477932-25-008185.md) | [(6,147)](/filings/0001477932-25-008185.md) | [(458)](/filings/0001477932-25-008185.md) | [(1,343) d](/filings/0001477932-26-001835.md) | [(1,679)](/filings/0001477932-26-004988.md) | [(1,542)](/filings/0001477932-26-004988.md) | [788](/filings/0001477932-25-008185.md) | [(593) d](/filings/0001477932-26-001835.md) | [(1,346)](/filings/0001477932-26-004988.md) | [(3,017)](/filings/0001477932-26-004988.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.03)](/filings/0001477932-25-003808.md) | [(0.07)](/filings/0001477932-25-005905.md) | [0.00](/filings/0001477932-25-008185.md) | not reported | [(0.09)](/filings/0001477932-26-003054.md) | [(0.08)](/filings/0001477932-26-004988.md) | [0.01](/filings/0001477932-25-008185.md) | not reported | [(0.06)](/filings/0001477932-26-003054.md) | [(0.11)](/filings/0001477932-26-004988.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | [0.00](/filings/0001477932-25-008185.md) | not reported | not reported | not reported | [0.01](/filings/0001477932-25-008185.md) | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.5](/filings/0001477932-23-008706.md) | [20.9](/filings/0001477932-24-003003.md) | [11.2](/filings/0001477932-24-003003.md) | [8.4](/filings/0001477932-24-004672.md) | [4.4](/filings/0001477932-24-007130.md) | [3.5](/filings/0001477932-25-002237.md) | [3.2](/filings/0001477932-25-003808.md) | [1.5](/filings/0001477932-25-005905.md) | [1.8](/filings/0001477932-25-008185.md) | [2.2](/filings/0001477932-26-001835.md) | [14.7](/filings/0001477932-26-003054.md) | [11.8](/filings/0001477932-26-004988.md) |
| Current assets | $m | [6.1](/filings/0001477932-23-008706.md) | [25.0](/filings/0001477932-25-002237.md) | [13.7](/filings/0001477932-24-003003.md) | [11.3](/filings/0001477932-24-004672.md) | [7.6](/filings/0001477932-24-007130.md) | [6.1](/filings/0001477932-26-001835.md) | [5.2](/filings/0001477932-25-003808.md) | [4.6](/filings/0001477932-25-005905.md) | [6.0](/filings/0001477932-25-008185.md) | [5.0](/filings/0001477932-26-004988.md) | [17.7](/filings/0001477932-26-003054.md) | [15.8](/filings/0001477932-26-004988.md) |
| Total assets | $m | [9.7](/filings/0001477932-23-008706.md) | [28.3](/filings/0001477932-25-002237.md) | [17.1](/filings/0001477932-24-003003.md) | [14.7](/filings/0001477932-24-004672.md) | [11.7](/filings/0001477932-24-007130.md) | [10.3](/filings/0001477932-26-001835.md) | [9.3](/filings/0001477932-25-003808.md) | [8.6](/filings/0001477932-25-005905.md) | [10.1](/filings/0001477932-25-008185.md) | [9.2](/filings/0001477932-26-004988.md) | [21.4](/filings/0001477932-26-003054.md) | [19.4](/filings/0001477932-26-004988.md) |
| Current liabilities | $m | [4.4](/filings/0001477932-23-008706.md) | [2.2](/filings/0001477932-25-002237.md) | [5.4](/filings/0001477932-24-003003.md) | [6.5](/filings/0001477932-24-004672.md) | [4.0](/filings/0001477932-24-007130.md) | [8.8](/filings/0001477932-26-001835.md) | [9.5](/filings/0001477932-25-003808.md) | [10.3](/filings/0001477932-25-005905.md) | [11.1](/filings/0001477932-25-008185.md) | [10.7](/filings/0001477932-26-004988.md) | [10.0](/filings/0001477932-26-003054.md) | [11.1](/filings/0001477932-26-004988.md) |
| Total liabilities | $m | [19.5](/filings/0001477932-23-008706.md) | [28.3](/filings/0001477932-25-002237.md) | [8.8](/filings/0001477932-24-003003.md) | [12.5](/filings/0001477932-24-004672.md) | [9.7](/filings/0001477932-24-007130.md) | [9.1](/filings/0001477932-26-001835.md) | [9.7](/filings/0001477932-25-003808.md) | [10.5](/filings/0001477932-25-005905.md) | [11.3](/filings/0001477932-25-008185.md) | [11.0](/filings/0001477932-26-004988.md) | [10.2](/filings/0001477932-26-003054.md) | [11.3](/filings/0001477932-26-004988.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(9.9)](/filings/0001477932-24-007130.md) | [0.1](/filings/0001477932-26-001835.md) | [8.8](/filings/0001477932-25-008185.md) | [2.8](/filings/0001477932-25-008185.md) | [2.5](/filings/0001477932-25-008185.md) | [1.2](/filings/0001477932-26-004988.md) | [(0.4)](/filings/0001477932-26-004988.md) | [(1.9)](/filings/0001477932-26-004988.md) | [(1.1)](/filings/0001477932-25-008185.md) | [(1.7)](/filings/0001477932-26-004988.md) | [11.2](/filings/0001477932-26-004988.md) | [8.2](/filings/0001477932-26-004988.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.6 d](/filings/0001477932-24-007130.md) | [18.4 d](/filings/0001477932-25-002237.md) | [(0.4)](/filings/0001477932-25-003808.md) | [(2.7) d](/filings/0001477932-25-005905.md) | [(0.2) d](/filings/0001477932-25-008185.md) | [(0.8) d](/filings/0001477932-26-001835.md) | [(0.3)](/filings/0001477932-26-003054.md) | [(1.7) d](/filings/0001477932-26-004988.md) | [0.3 d](/filings/0001477932-25-008185.md) | [1.0 d](/filings/0001477932-26-001835.md) | [(2.2)](/filings/0001477932-26-003054.md) | [(2.8) d](/filings/0001477932-26-004988.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001477932-24-007130.md) | [(0.0) d](/filings/0001477932-25-002237.md) | [0.0](/filings/0001477932-25-003808.md) | [0.1 d](/filings/0001477932-25-005905.md) | [0.6 d](/filings/0001477932-25-008185.md) | [0.1 d](/filings/0001477932-26-001835.md) | [0.0](/filings/0001477932-26-003054.md) | [0.0 d](/filings/0001477932-26-004988.md) | [0.0 d](/filings/0001477932-25-008185.md) | [0.0 d](/filings/0001477932-26-001835.md) | [0.0](/filings/0001477932-26-003054.md) | [0.1 d](/filings/0001477932-26-004988.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2018 (2018-03-31) | Q1 FY2019 (2019-03-31) | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [75.9](/filings/0001477932-19-002822.md) | [76.3](/filings/0001477932-19-002822.md) | [93.5](/filings/0001477932-23-008706.md) | [94.3](/filings/0001477932-23-008706.md) | [94.4](/filings/0001477932-25-003808.md) | [94.5](/filings/0001477932-25-005905.md) | [96.1](/filings/0001477932-25-008185.md) | [19.2](/filings/0001477932-26-003054.md) | [19.3](/filings/0001477932-26-004988.md) | [98.0](/filings/0001477932-25-008185.md) | [21.8](/filings/0001477932-26-003054.md) | [26.3](/filings/0001477932-26-004988.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,305,966 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001477932-26-004988.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.